

**Preliminary Amendment filed February 28, 2005
U.S. Patent Application Serial No. (not yet assigned)**

IN THE CLAIMS:

This listing of claims will replace all prior versions, and listings, of the claims in the application:

Listing of Claims:

Claim 1 (Currently Amended): A remedy wherein phagocytic activity of macrophages is ~~induced~~ facilitated and all or a part of the pathogens present in the macrophages are exterminated to vanish.

Claim 2 (Currently Amended): A remedy wherein phagocytic activity of macrophages is ~~induced~~ facilitated and pathogen-retaining macrophages are led to cell death.

Claim 3 (Currently Amended): A remedy wherein phagocytic activity of macrophages is ~~induced~~ facilitated and it acted upon the macrophages in a dysfunctional state.

Claim 4 (Currently Amended): The remedy according to Claim 1 ~~or~~ 2, for mycobacteriosis, AIDS, chlamydiosis or toxoplasmosis.

Claim 5 (Currently Amended): The remedy according to Claim 2 ~~or~~ 3, for Crohn's disease, rheumatoid, cancer or immunodeficiency syndrome.

**Preliminary Amendment filed February 28, 2005
U.S. Patent Application Serial No. (not yet assigned)**

Claim 6 (Currently Amended): The remedy according to ~~Claims 1 to 4~~ Claim 1, wherein said macrophages are resident in mucosal tissue.

Claim 7 (Currently Amended): The remedy according to ~~Claims 1 to 4~~ Claim 1, wherein said macrophages are resident in any of peritoneal cavity, greater omentum, milky spot, pulmonary alveolus, pulmonary stroma, liver, portal vein area, spleen, bone marrow, thymus, digestive tract, palatine tonsil, adrenal gland, pituitary, thyroid stroma, Langerhans islet, parathyroid gland, pineal gland, testis, ovary, oviduct, uterus, placenta, skin, meninges, brain substance and choroid plexus, or the above macrophages are microglia, precursor cells of microglia, glia cells, precursor cells of glia cells, precursor cells of the above resident macrophages, analogous cells of the above resident macrophages, or precursor cells of the above resident macrophage analogous cells.

Claim 8 (Currently Amended): The remedy according to Claim 1, ~~2, 3 or 6~~, comprising PLGA [poly(lactic acid/glycolic acid)copolymer] and being for tuberculosis.

Claim 9 (Original): The remedy according to Claim 8, further comprising rifampicin.

Claim 10 (Currently Amended): The remedy according to ~~Claims 1 to 9~~, Claim 1, comprising PLGA where a molecular weight is 1,500 to 150,000.

**Preliminary Amendment filed February 28, 2005
U.S. Patent Application Serial No. (not yet assigned)**

Claim 11 (Currently Amended): The remedy according to ~~Claims 1 to 9~~, Claim 1, comprising PLGA where a molecular weight is 1,500 to 75,000.

Claim 12 (Currently Amended): The remedy according to ~~any of Claims 1 to 11~~, Claim 1, further comprising at least one of PVA (polyvinyl alcohol), PEG (polyethyleneglycol), PEO (polyethylene oxide), sugar, protein, peptide, phospholipid or cholesterol.

Claim 13 (Currently Amended): The remedy according to Claim 8 ~~or 9~~, comprising at least one of PVA, PEG, PEO, sugar, protein, peptide, phospholipid or cholesterol, and being a fine particle formulation wherein major particle diameters are 1 to 6 μm .

Claim 14 (New): The remedy according to Claim 1, wherein the phagocytic activity of the macrophages is facilitated by being phagocytosed.

Claim 15 (New): The remedy according to Claim 1, comprising PLGA where a molecular weight is 5,000 to 20,000 and being for tuberculosis.

Claim 16 (New): The remedy according to Claim 15, fabricated by membrane emulsification method.

Preliminary Amendment filed February 28, 2005
U.S. Patent Application Serial No. (not yet assigned)

Claim 17 (New): The remedy according to Claim 2, comprising lipopolysaccharide of *Pantoea agglomerans* and being for AIDS.

Claim 18 (New): The remedy according to Claim 3, comprising lipopolysaccharide of *Pantoea agglomerans* and having cytotoxic effect on lung cancer cells.